DELTICOM
7.4.2016 15:07:25 CEST | Business Wire | Press release
Springtime is tyre-changing time. However, some people who have been driving on old winter tyres might consider wearing them out completely by leaving them for all summer, thus saving themselves the cost of having the tyres changed as well as the possible cost of a new set of summer tyres. By doing so, they sacrifice their own safety and purchasing efficiency.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160407005795/en/
The properties of summer and winter tyres are designed to meet the specific requirements of weather conditions at different times of year. In this way, they ensure optimum efficiency and safety in the prevailing weather conditions. While it may be very tempting to drive straight through to autumn on winter tyres, in warm temperatures summer tyres are a better choice. The general rule of thumb is: from Easter to October. Once the average temperature is mostly above seven degrees Celsius, summer tyres show off all their advantages.
Even Germany’s largest automobile association, ADAC, warns against driving on winter tyres during summer. The reason: due to the soft tread compound used in winter tyres, they are not suited to warm temperatures and offer less grip. When the weather gets warmer, the tread quickly wears off and braking performance is significantly affected. ADAC tests on winter tyres have shown that in summer, stopping distances at approx. 60mph/h may be extended by up to 16 metres. If tyres are also heated further through heavy vehicle loads, winter tyre side walls can suffer damage, and parts of the tread can even come unstuck.
“We recommend changing to summer tyres now, because they are the only tyres that offer the right custom profile and special rubber compound for warmer weather and therefore ensure good grip and shorter breaking distances”, advises Thierry Delesalle from Mytyres.co.uk. “If you’re thinking of leaving your winter tyres on, you won’t do your wallet any favours: in warm weather, winter tyres can increase fuel consumption by up to 15%”, explains Delesalle.
So save now and hit the road properly equipped: just click on Mytyres.co.uk and enjoy a wide range of suitable summer tyres at great prices - quickly, easily and securely. Tyres can be delivered either to the customer’s preferred address, or to one of over 2,000 partner fitting stations across the UK. Many partner workshops also offer customers competitive prices for storing their winter tyres at the workshop until the following winter.
The most important hints on the changing of summer tyres can be also found in the following video: https://www.youtube.com/watch?v=OE5wWgUmi2k&nohtml5
About Mytyres.co.uk
There are over 100 tyre brands and more than 25,000 models of tyres to be found at Mytyres.co.uk - also including the latest best-rated tyres from official comparison tests. The product portfolio not only includes tyres for cars , motorbikes , lorries, commercial vehicles and buses , but also wheel-tyre sets , rims and car replacement parts and accessories . Particularly practical: new tyres can be delivered quickly and free of charge* to any address provided. When purchasing tyres, buyers can also choose from more than 2,000 professional car workshop partners across the UK and have the tyres sent to them directly for professional fitting. Many of our partner workshops offer also additional services, such as tyre storage.
*2 tyres and more
Buy tyres online:
www.mytyres.co.uk , www.reifendirekt.de , www.reifendirekt.at , www.reifendirekt.ch , www.123pneus.ch , www.autobandenmarkt.nl , www.123pneus.fr , www.gommadiretto.it , www.neumaticos-online.es and in many other Delticom online shops.
Tyre tests: www.tyretest.com
Information about the company: www.delti.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160407005795/en/
Contact:
insignis Agency for Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
